Pherecydes Pharma Logo

Pherecydes Pharma

Develops precision phage therapy to treat resistant bacterial infections.

ALPHE | PA

Overview

Corporate Details

ISIN(s):
FR0011651694
LEI:
894500LYT3UUN58X3I68
Country:
France
Address:
22 BD BENONI GOULLIN, NANTES BIOTECH, 44200 NANTES
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Pherecydes Pharma is a biotechnology company that specializes in developing treatments for resistant bacterial infections. The company pioneers precision phage therapy, an approach that uses bacteriophage viruses (phages) to specifically target and combat harmful bacteria. This personalized therapeutic strategy is designed to treat severe and complicated infections that are unresponsive to conventional antibiotics. Founded in 2006, the company focuses on creating a portfolio of phages effective against critical bacterial pathogens. In June 2023, Pherecydes Pharma merged with Erytech Pharma to become Phaxiam Therapeutics, continuing its work in the fight against antimicrobial resistance.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2023-06-23 20:45
Post-Annual General Meeting Information
Informations privilégiées / Autres communiqués
French 214.3 KB
2023-06-23 20:45
Post-Annual General Meeting Information
Inside Information / Other news releases
English 213.8 KB
2023-06-14 20:00
Legal Proceedings Report
Inside Information / Other news releases
English 197.1 KB
2023-06-14 20:00
Legal Proceedings Report
Informations privilégiées / Autres communiqués
French 200.6 KB
2023-06-08 07:30
Legal Proceedings Report
Informations privilégiées / Autres communiqués
French 297.3 KB
2023-06-08 07:30
Regulatory News Service
Inside Information / Other news releases
English 269.4 KB
2023-06-05 08:00
Legal Proceedings Report
Inside Information / Other news releases
English 198.4 KB
2023-06-05 08:00
Legal Proceedings Report
Informations privilégiées / Autres communiqués
French 192.1 KB
2023-06-02 20:00
Pre-Annual General Meeting Information
Modalités de mise à disposition des documents préparatoires à l'AG
French 152.4 KB
2023-05-23 23:43
M&A Activity
News releases during takeover bids / Takeover bids Other news releases
English 191.8 KB
2023-05-23 23:43
Registration Form
Communiqués publiés en période d'offre publique d'acquisition / OPA Autres comm…
French 184.9 KB
2023-05-16 07:00
M&A Activity
Inside Information / Other news releases
English 224.2 KB
2023-05-16 07:00
M&A Activity
Informations privilégiées / Autres communiqués
French 216.3 KB
2023-05-11 18:00
Capital/Financing Update
Acquisition ou cession des actions de l'émetteur / Information relative au cont…
French 200.6 KB
2023-04-27 18:00
Report Publication Announcement
Rapports financiers et d'audit annuels / Modalités de mise à disposition du rap…
French 195.2 KB

Automate Your Workflow. Get a real-time feed of all Pherecydes Pharma filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Pherecydes Pharma via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Orexo Logo
Develops pharmaceuticals & digital health for opioid use disorder in the US market.
Sweden ORX
Orion Oyj Logo
Develops and manufactures human/vet pharma, APIs, and generics for global markets.
Finland ORNAV
Orum Therapeutics, Inc. Logo
Developing degrader-antibody conjugates for cell-selective protein degradation to treat cancer.
South Korea 475830
Otsuka Holdings Co., Ltd. Logo
Global healthcare group creating pharmaceuticals and nutraceuticals for worldwide well-being.
Japan 4578
Ovoca Bio Plc Logo
Biopharma developing a novel therapy for premenopausal women with low sexual desire (HSDD).
Ireland OVXA
Oxford Biomedica PLC Logo
A CDMO for cell & gene therapy, providing end-to-end viral vector development & manufacturing.
United Kingdom OXB
OXFORD CANNABINOID TECHNOLOGIES HOLDINGS PLC Logo
A former biopharma firm that developed non-addictive, cannabinoid-based pain therapies.
United Kingdom OCTHF
PAION AG Logo
Developed drugs for hospital-based sedation, anesthesia, and critical care.
Germany PA8
Pangen Biotech Inc. Logo
Develops biosimilars and provides CHO-based CDMO services for the global biopharma industry.
South Korea 222110
Pentixapharm Holding AG Logo
Develops radiopharmaceuticals for diagnosing and treating oncology and adrenal disorders.
Germany PTP

Talk to a Data Expert

Have a question? We'll get back to you promptly.